Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Eisai Begins PI Study for BAN2401 in the US
September 13, 2010
- Korosho Demands ¥28,795.4 Bil. General Account Budget for FY2011
September 13, 2010
- Humira Applied for JIA in Japan: Abbott, Eisai
September 13, 2010
- No Significant Differences in ADRs between Avandia, Actos: HealthCore
September 13, 2010
- Korosho Demands Budgets to Develop Buried Seeds of Drugs
September 13, 2010
- FDA Extends Review of Eribulin NDA: Eisai
September 13, 2010
- Expand Range of Indications for Palivizumab: Dr Watabe
September 13, 2010
- Working Groups Created to Assess 8 Vaccines
September 13, 2010
- SRSM Created to Promote Regulatory Sciences
September 13, 2010
- Appeal Trial Begins on Online Sale of Classes 1, 2 OTC Drugs
September 13, 2010
- Addition of New Indications Unlikely to Make Any Drugs Eligible for Re-Pricing
September 13, 2010
- Sawai, Medisa to Recall Generics for Bromocriptine
September 13, 2010
- Orencia to Boost BMKK's Sales
September 13, 2010
- Nippon Kayaku Applies for Hycamtin Based on Data from Public Domain
September 13, 2010
- NEW PRODUCTS
September 6, 2010
- Chuikyo Recommends Reimbursement before Approval Based on Data from Public Domain
September 6, 2010
- Approval of Takepron for Prevention of Ulcers Is a Major Landmark: Prof. Sugano
September 6, 2010
- Korosho Considers Introduction of a CU System
September 6, 2010
- Fuso Applies for Buprenorphine for PHN
September 6, 2010
- MTPC Completes All-Patient PMS on Remicade for Uveoretinitis
September 6, 2010
ページ
The launch of Elevidys has opened the door to gene therapy for DMD, but research into new treatments is already…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…